IE58235B1 - Bromocriptine compositions - Google Patents
Bromocriptine compositionsInfo
- Publication number
- IE58235B1 IE58235B1 IE49585A IE49585A IE58235B1 IE 58235 B1 IE58235 B1 IE 58235B1 IE 49585 A IE49585 A IE 49585A IE 49585 A IE49585 A IE 49585A IE 58235 B1 IE58235 B1 IE 58235B1
- Authority
- IE
- Ireland
- Prior art keywords
- formulation according
- bromocriptine
- fatty material
- capsule
- weight ratio
- Prior art date
Links
- 229960002802 bromocriptine Drugs 0.000 title claims abstract description 54
- OZVBMTJYIDMWIL-AYFBDAFISA-N bromocriptine Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 OZVBMTJYIDMWIL-AYFBDAFISA-N 0.000 title claims abstract description 53
- 239000000203 mixture Substances 0.000 title claims description 53
- 239000000463 material Substances 0.000 claims abstract description 14
- 239000000126 substance Substances 0.000 claims abstract description 12
- 238000013270 controlled release Methods 0.000 claims abstract description 8
- 238000009472 formulation Methods 0.000 claims description 35
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 15
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 11
- 230000008961 swelling Effects 0.000 claims description 9
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 6
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 6
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical group OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 6
- 238000002844 melting Methods 0.000 claims description 5
- 230000008018 melting Effects 0.000 claims description 5
- 125000005456 glyceride group Chemical group 0.000 claims description 4
- 238000000338 in vitro Methods 0.000 claims description 3
- 206010000599 Acromegaly Diseases 0.000 claims description 2
- 208000018737 Parkinson disease Diseases 0.000 claims description 2
- 229920002678 cellulose Polymers 0.000 claims description 2
- 239000001913 cellulose Substances 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims description 2
- 238000002474 experimental method Methods 0.000 claims description 2
- 239000000416 hydrocolloid Substances 0.000 claims description 2
- 208000031424 hyperprolactinemia Diseases 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 230000002209 hydrophobic effect Effects 0.000 claims 1
- 239000002775 capsule Substances 0.000 description 41
- 239000004615 ingredient Substances 0.000 description 18
- 230000000694 effects Effects 0.000 description 12
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 10
- 102000003946 Prolactin Human genes 0.000 description 9
- 108010057464 Prolactin Proteins 0.000 description 9
- 229940079593 drug Drugs 0.000 description 9
- 239000003814 drug Substances 0.000 description 9
- 229940097325 prolactin Drugs 0.000 description 9
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 7
- 239000008101 lactose Substances 0.000 description 7
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 5
- FLPJVCMIKUWSDR-UHFFFAOYSA-N 2-(4-formylphenoxy)acetamide Chemical compound NC(=O)COC1=CC=C(C=O)C=C1 FLPJVCMIKUWSDR-UHFFFAOYSA-N 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 4
- 229940074979 cetyl palmitate Drugs 0.000 description 4
- 235000014113 dietary fatty acids Nutrition 0.000 description 4
- 239000000194 fatty acid Substances 0.000 description 4
- 229930195729 fatty acid Natural products 0.000 description 4
- 229920000159 gelatin Polymers 0.000 description 4
- 235000019322 gelatine Nutrition 0.000 description 4
- PXDJXZJSCPSGGI-UHFFFAOYSA-N hexadecanoic acid hexadecyl ester Natural products CCCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCC PXDJXZJSCPSGGI-UHFFFAOYSA-N 0.000 description 4
- 239000000902 placebo Substances 0.000 description 4
- 229940068196 placebo Drugs 0.000 description 4
- 239000000377 silicon dioxide Substances 0.000 description 4
- 239000001828 Gelatine Substances 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- -1 for example Chemical class 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 230000002045 lasting effect Effects 0.000 description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- IZHVBANLECCAGF-UHFFFAOYSA-N 2-hydroxy-3-(octadecanoyloxy)propyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCCCCCCCCCCC IZHVBANLECCAGF-UHFFFAOYSA-N 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- 206010028813 Nausea Diseases 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000003136 dopamine receptor stimulating agent Substances 0.000 description 2
- 230000003291 dopaminomimetic effect Effects 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- 125000005908 glyceryl ester group Chemical group 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 239000011976 maleic acid Substances 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
- 230000008693 nausea Effects 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- 229940124531 pharmaceutical excipient Drugs 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- HLZKNKRTKFSKGZ-UHFFFAOYSA-N tetradecan-1-ol Chemical compound CCCCCCCCCCCCCCO HLZKNKRTKFSKGZ-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- QHZLMUACJMDIAE-UHFFFAOYSA-N 1-monopalmitoylglycerol Chemical class CCCCCCCCCCCCCCCC(=O)OCC(O)CO QHZLMUACJMDIAE-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical group OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 102220487426 Actin-related protein 2/3 complex subunit 3_K15M_mutation Human genes 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 229910002016 Aerosil® 200 Inorganic materials 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 241000206575 Chondrus crispus Species 0.000 description 1
- 208000002881 Colic Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 241000557626 Corvus corax Species 0.000 description 1
- 241001440269 Cutina Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 229920000569 Gum karaya Polymers 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 206010021082 Hypoprolactinaemia Diseases 0.000 description 1
- 206010021118 Hypotonia Diseases 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 229920000161 Locust bean gum Polymers 0.000 description 1
- 229920003091 Methocel™ Polymers 0.000 description 1
- 229920003102 Methocel™ E4M Polymers 0.000 description 1
- 208000007379 Muscle Hypotonia Diseases 0.000 description 1
- 206010028735 Nasal congestion Diseases 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 241000934878 Sterculia Species 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229940023476 agar Drugs 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 229940096529 carboxypolymethylene Drugs 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 239000013256 coordination polymer Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229940074045 glyceryl distearate Drugs 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- FETSQPAGYOVAQU-UHFFFAOYSA-N glyceryl palmitostearate Chemical compound OCC(O)CO.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O FETSQPAGYOVAQU-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 235000010494 karaya gum Nutrition 0.000 description 1
- 239000000231 karaya gum Substances 0.000 description 1
- 229940039371 karaya gum Drugs 0.000 description 1
- 235000010420 locust bean gum Nutrition 0.000 description 1
- 239000000711 locust bean gum Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 229940043348 myristyl alcohol Drugs 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 230000002746 orthostatic effect Effects 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 229960000292 pectin Drugs 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 239000011369 resultant mixture Substances 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 229940012831 stearyl alcohol Drugs 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000003867 tiredness Effects 0.000 description 1
- 208000016255 tiredness Diseases 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical class [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB848405227A GB8405227D0 (en) | 1984-02-29 | 1984-02-29 | Bromocriptine compositions |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IE850495L IE850495L (en) | 1985-08-29 |
| IE58235B1 true IE58235B1 (en) | 1993-08-11 |
Family
ID=10557324
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IE49585A IE58235B1 (en) | 1984-02-29 | 1985-02-28 | Bromocriptine compositions |
Country Status (26)
| Country | Link |
|---|---|
| JP (1) | JPS60202812A (ru) |
| AT (1) | AT387716B (ru) |
| AU (2) | AU586621B2 (ru) |
| BE (1) | BE901810A (ru) |
| CA (1) | CA1256374A (ru) |
| CH (2) | CH666406A5 (ru) |
| DE (1) | DE3505743C2 (ru) |
| DK (1) | DK175016B1 (ru) |
| ES (1) | ES8705223A1 (ru) |
| FR (1) | FR2560047B1 (ru) |
| GB (1) | GB8405227D0 (ru) |
| GR (1) | GR850506B (ru) |
| HK (1) | HK85490A (ru) |
| HU (1) | HU196121B (ru) |
| IE (1) | IE58235B1 (ru) |
| IL (1) | IL74459A (ru) |
| IT (1) | IT1199948B (ru) |
| LU (1) | LU85791A1 (ru) |
| MX (1) | MX9203626A (ru) |
| NL (1) | NL194231C (ru) |
| NZ (1) | NZ211247A (ru) |
| PH (1) | PH23266A (ru) |
| PT (1) | PT80015B (ru) |
| SE (2) | SE8500961L (ru) |
| SG (1) | SG69390G (ru) |
| ZA (1) | ZA851546B (ru) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU4064285A (en) * | 1984-03-21 | 1985-10-11 | American Home Products Corporation | Sustained release pharmaceutical capsules |
| DE3722383A1 (de) * | 1986-07-14 | 1988-01-28 | Sandoz Ag | Neue verwendung von bromocriptin |
| DE4041563A1 (de) * | 1990-12-22 | 1992-06-25 | Sanol Arznei Schwarz Gmbh | Verfahren zur herstellung wirkstoffhaltiger mikropartikel aus hydrolytisch abbaubaren polymeren |
| EP0689424B1 (en) * | 1993-03-17 | 1998-10-14 | Minnesota Mining And Manufacturing Company | Aerosol formulation containing an ester-, amide-, or mercaptoester-derived dispersing aid |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL128902C (ru) * | 1960-06-06 | |||
| CH507249A (de) * | 1968-05-31 | 1971-05-15 | Sandoz Ag | Verfahren zur Herstellung von 2-Brom-a-ergokryptin |
| DE2553026A1 (de) * | 1974-12-04 | 1976-06-10 | Schlueter Edelfett | Neue formulierungen |
| CH630257A5 (en) * | 1975-03-17 | 1982-06-15 | Hoffmann La Roche | Sustained release formulation |
| IT1158162B (it) * | 1977-12-22 | 1987-02-18 | Sandoz Ag | Composizioni farmaceutiche a base di derivati dell'ergolena e dell'ergolina |
| DE3045135A1 (de) * | 1980-11-29 | 1982-06-09 | Sandoz-Patent-GmbH, 7850 Lörrach | Pharmazeutische kompositionen enthaltende bioabbaubare polymere |
| US4369172A (en) * | 1981-12-18 | 1983-01-18 | Forest Laboratories Inc. | Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose |
| DE3216870A1 (de) * | 1982-05-03 | 1983-11-03 | Schering AG, 1000 Berlin und 4709 Bergkamen | Pharmazeutische zubereitungen mit zytostatischer wirkung |
| US4559222A (en) * | 1983-05-04 | 1985-12-17 | Alza Corporation | Matrix composition for transdermal therapeutic system |
-
1983
- 1983-12-14 CH CH6660/83A patent/CH666406A5/de not_active IP Right Cessation
-
1984
- 1984-02-29 GB GB848405227A patent/GB8405227D0/en active Pending
-
1985
- 1985-02-14 HU HU85555A patent/HU196121B/hu unknown
- 1985-02-14 NL NL8500417A patent/NL194231C/nl not_active IP Right Cessation
- 1985-02-20 DE DE3505743A patent/DE3505743C2/de not_active Expired - Lifetime
- 1985-02-20 IT IT47703/85A patent/IT1199948B/it active
- 1985-02-22 FR FR8502716A patent/FR2560047B1/fr not_active Expired
- 1985-02-22 CH CH830/85A patent/CH667009A5/de not_active IP Right Cessation
- 1985-02-25 BE BE1/11199A patent/BE901810A/fr not_active IP Right Cessation
- 1985-02-26 DK DK198500867A patent/DK175016B1/da active Protection Beyond IP Right Term
- 1985-02-26 AU AU39136/85A patent/AU586621B2/en not_active Expired
- 1985-02-26 CA CA000475119A patent/CA1256374A/en not_active Expired
- 1985-02-27 SE SE8500961D patent/SE8500961L/xx not_active Application Discontinuation
- 1985-02-27 NZ NZ211247A patent/NZ211247A/xx unknown
- 1985-02-27 JP JP60040277A patent/JPS60202812A/ja active Granted
- 1985-02-27 IL IL74459A patent/IL74459A/xx not_active IP Right Cessation
- 1985-02-27 GR GR850506A patent/GR850506B/el not_active IP Right Cessation
- 1985-02-27 SE SE8500961A patent/SE462259B/sv unknown
- 1985-02-27 PT PT80015A patent/PT80015B/pt unknown
- 1985-02-27 LU LU85791A patent/LU85791A1/fr unknown
- 1985-02-27 AT AT0058085A patent/AT387716B/de not_active IP Right Cessation
- 1985-02-28 PH PH31923A patent/PH23266A/en unknown
- 1985-02-28 ES ES540807A patent/ES8705223A1/es not_active Expired
- 1985-02-28 ZA ZA851546A patent/ZA851546B/xx unknown
- 1985-02-28 IE IE49585A patent/IE58235B1/en not_active IP Right Cessation
-
1989
- 1989-05-19 AU AU35006/89A patent/AU618599B2/en not_active Expired
-
1990
- 1990-08-22 SG SG693/90A patent/SG69390G/en unknown
- 1990-10-18 HK HK854/90A patent/HK85490A/xx not_active IP Right Cessation
-
1992
- 1992-06-26 MX MX9203626A patent/MX9203626A/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5624677A (en) | Controlled release of drugs delivered by sublingual or buccal administration | |
| JP4948691B2 (ja) | 舌下又は頬投与によって送達される薬物の徐放 | |
| US20110177168A1 (en) | Composition | |
| US10821118B2 (en) | Oral transmucosal drug delivery system | |
| GB2154874A (en) | Bromocriptine compositions | |
| AU2004275469A1 (en) | HRT formulations | |
| NZ220769A (en) | Compositions of ketotifen (4-(1-methyl-4-piperidylidene)- 4h-benzo(4,5)cyclohepta(1,2-b)thiophen-10-9(h)-one) | |
| AU597570B2 (en) | Pharmaceutical 9,10-dehydrogenated ergot alkaloid containing compositions | |
| CA1256374A (en) | Bromocriptine compositions | |
| PT85880B (pt) | Processo para a preparacao de composicoes farmaceuticas de accao retardada contendo como substancia veicular uma mistura de celulose microcristalina com hidroxipropil-metilcelulose | |
| US5069911A (en) | Pharmaceutical 9,10-dihydrogenated ergot alkaloid containing compositions | |
| JP2001511450A (ja) | チアガビンを含有する制御放出性の医薬組成物 | |
| KR920008817B1 (ko) | 조절된 방출성(서방성) 약학적 제제의 제조방법. | |
| KR960008229B1 (ko) | 캡토프릴 서방성 정제 및 그의 제조방법 | |
| JPH047323B2 (ru) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK9A | Patent expired |